Pain Research Center and Department of Physiology, Zhongshan Medical School of Sun Yat-Sen University, China.
Pain Physician. 2013 Sep-Oct;16(5):E563-75.
Clinical studies have shown that about two-thirds of patients with chronic pain suffer from short-term memory (STM) deficits and an effective drug for treatment of the neurological disorder is lacking at present.
We tested whether chronic oral application of magnesium L-threonate (MgT), which has been shown to improve memory in normal and aging animals by elevating Mg2+ in the brain, could prevent or restore the STM deficits induced by spared nerve injury (SNI), an animal model of chronic neuropathic pain. The mechanisms underlying the effect of MgT on STM deficits were also investigated.
The experiments were conducted in a random and double-blind fashion in adult male rats. MgT was administrated via drinking water at a dose of 609 mg/kg/d for 2 weeks, starting either one week before SNI (preventative group) or one week after SNI (therapeutic group), and water without the drug served as control.
STM was accessed with a novel object recognition test (NORT), followed by recording of long-term potentiation (LTP) in the hippocampus in vivo and the measurement of the expression of tumor necrosis factor-α (TNF-α) with Western Blot or Immunohistochemistrical staining, a-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) and N-methyl-D-aspartic acid (NMDA) receptor (NMDAR) currents were recorded with patch clamp in CA1 neurons in acute and cultured hippocampal slices.
We found that chronic oral application of MgT was able to prevent and restore the deficits of STM and of LTP at CA3-CA1 synapses in the hippocampus induced by SNI. Furthermore, both preventative and therapeutic chronic oral application of MgT blocked the up-regulation of TNF-α in the hippocampus, which has been previously shown to be critical for memory deficits. SNI reduced NMDAR current and the effect was dramatically attenuated by elevating extracellular Mg2+ concentration ([Mg2+]○). In cultured hippocampal slices, chronic application of recombinant rat TNF-α (rrTNF-α) for 3 days reduced NMDAR current in a concentration-dependent manner and the effect was again blocked by elevating [Mg2+]○.
We showed that oral application of MgT inhibited the over-expression of TNF-α and rescued the dysfunction of the NMDAR, but the causal relationship between them remains elusive.
Our data suggested that oral application of MgT was able to prevent and restore the STM deficits in an animal model of chronic neuropathic pain by reversing the dysfunction of the NMDAR, and normalization of TNF-α expression may play a role in the effect. Oral application of MgT may be a simple and potent means for handling this form of memory deficit.
临床研究表明,约三分之二的慢性疼痛患者存在短期记忆(STM)缺陷,目前缺乏有效的治疗神经紊乱的药物。
我们测试了慢性口服给予 L-苏糖酸镁(MgT)是否可以预防或恢复 spared nerve injury(SNI)引起的 STM 缺陷,SNI 是一种慢性神经病理性疼痛的动物模型。MgT 对 STM 缺陷的影响的机制也进行了研究。
实验在成年雄性大鼠中以随机和双盲的方式进行。MgT 通过饮用水给药,剂量为 609mg/kg/d,持续 2 周,给药时间分别为 SNI 前一周(预防组)或 SNI 后一周(治疗组),未添加药物的水作为对照。
使用新物体识别测试(NORT)评估 STM,随后在体内记录海马长时程增强(LTP),并使用 Western Blot 或免疫组织化学染色测量肿瘤坏死因子-α(TNF-α)的表达,使用膜片钳技术在急性和培养的海马切片中记录 α-氨基-3-羟基-5-甲基-4-异恶唑丙酸(AMPA)和 N-甲基-D-天冬氨酸(NMDA)受体(NMDAR)电流。
我们发现,慢性口服给予 MgT 能够预防和恢复 SNI 诱导的海马 CA3-CA1 突触的 STM 和 LTP 缺陷。此外,预防性和治疗性慢性口服给予 MgT 均能阻断海马 TNF-α的上调,此前研究表明 TNF-α的上调与记忆缺陷有关。SNI 降低了 NMDAR 电流,而提高细胞外镁离子浓度([Mg2+]○)则显著减弱了这种作用。在培养的海马切片中,重组大鼠 TNF-α(rrTNF-α)连续 3 天给药呈浓度依赖性降低 NMDAR 电流,而提高 [Mg2+]○则阻断了这种作用。
我们表明,口服给予 MgT 抑制了 TNF-α的过度表达,并挽救了 NMDAR 的功能障碍,但它们之间的因果关系仍不清楚。
我们的数据表明,口服给予 MgT 通过逆转 NMDAR 的功能障碍,能够预防和恢复慢性神经病理性疼痛动物模型中的 STM 缺陷,TNF-α表达的正常化可能在其中发挥作用。口服给予 MgT 可能是处理这种形式的记忆缺陷的一种简单而有效的方法。